L J Hofland

Summary

Affiliation: Erasmus MC
Country: The Netherlands

Publications

  1. ncbi Ghrelin drives GH secretion during fasting in man
    Alex F Muller
    Division of Endocrinology, Department of Internal Medicine, Erasmus University Medical Centre, Rotterdam, The Netherlands
    Eur J Endocrinol 146:203-7. 2002
  2. ncbi Cortistatin rather than somatostatin as a potential endogenous ligand for somatostatin receptors in the human immune system
    Virgil A Dalm
    Department of Internal Medicine, Erasmus Medical Center, 3015 GD, Rotterdam, The Netherlands
    J Clin Endocrinol Metab 88:270-6. 2003
  3. ncbi Immunoreactivity score using an anti-sst2A receptor monoclonal antibody strongly predicts the biochemical response to adjuvant treatment with somatostatin analogs in acromegaly
    Federico Gatto
    Department of Internal Medicine, Erasmus MC, 3015 GE Rotterdam, The Netherlands
    J Clin Endocrinol Metab 98:E66-71. 2013
  4. ncbi Somatostatin and somatostatin receptors in Cushing's disease
    Leo J Hofland
    Department of Internal Medicine, Division Endocrinology, Erasmus MC, Rotterdam, The Netherlands
    Mol Cell Endocrinol 286:199-205. 2008
  5. ncbi The somatostatin receptor subtype 5 in neuroendocrine tumours
    Joost van der Hoek
    Department of Internal Medicine, Division of Endocrinology, Room Ee530b, Erasmus MC, Dr Molewaterplein 50, 3015 GE Rotterdam, The Netherlands
    Expert Opin Investig Drugs 19:385-99. 2010
  6. ncbi Responsiveness to somatostatin analog treatment and potentials of novel somatostatin analog
    L J Hofland
    Department of Internal Medicine, Section Endocrinology, Erasmus MC, Rotterdam, The Netherlands
    J Endocrinol Invest 26:8-13. 2003
  7. ncbi Pre-clinical and clinical experiences with novel somatostatin ligands: advantages, disadvantages and new prospects
    L J Hofland
    Department of Internal Medicine, Section Endocrinology, Erasmus MC, Rotterdam, The Netherlands
    J Endocrinol Invest 28:36-42. 2005
  8. ncbi The novel somatostatin analog SOM230 is a potent inhibitor of hormone release by growth hormone- and prolactin-secreting pituitary adenomas in vitro
    Leo J Hofland
    Department of Internal Medicine, Section of Endocrinology, Erasmus Medical Center, 3015 GD Rotterdam, The Netherlands
    J Clin Endocrinol Metab 89:1577-85. 2004
  9. ncbi Role of somatostatin receptors in normal and tumoral pituitary corticotropic cells
    Leo J Hofland
    Department of Internal Medicine, Division of Endocrinology, Erasmus MC, Rotterdam, The Netherlands
    Neuroendocrinology 92:11-6. 2010
  10. ncbi Pituitary tumours: the sst/D2 receptors as molecular targets
    Leo J Hofland
    Department of Internal Medicine, Division of Endocrinology, Erasmus Medical Center, Rotterdam, The Netherlands
    Mol Cell Endocrinol 326:89-98. 2010

Collaborators

Detail Information

Publications110 found, 100 shown here

  1. ncbi Ghrelin drives GH secretion during fasting in man
    Alex F Muller
    Division of Endocrinology, Department of Internal Medicine, Erasmus University Medical Centre, Rotterdam, The Netherlands
    Eur J Endocrinol 146:203-7. 2002
    ....
  2. ncbi Cortistatin rather than somatostatin as a potential endogenous ligand for somatostatin receptors in the human immune system
    Virgil A Dalm
    Department of Internal Medicine, Erasmus Medical Center, 3015 GD, Rotterdam, The Netherlands
    J Clin Endocrinol Metab 88:270-6. 2003
    ..On the basis of these observations, we hypothesize a role for CST as an endogenous ligand of at least the sst2 receptor in the human immune system, rather than SS itself...
  3. ncbi Immunoreactivity score using an anti-sst2A receptor monoclonal antibody strongly predicts the biochemical response to adjuvant treatment with somatostatin analogs in acromegaly
    Federico Gatto
    Department of Internal Medicine, Erasmus MC, 3015 GE Rotterdam, The Netherlands
    J Clin Endocrinol Metab 98:E66-71. 2013
    ..Recently, a new rabbit monoclonal anti-sst2A antibody (clone UMB-1) has been validated as a reliable method to selectively detect sst2A protein levels in formalin-fixed tissues...
  4. ncbi Somatostatin and somatostatin receptors in Cushing's disease
    Leo J Hofland
    Department of Internal Medicine, Division Endocrinology, Erasmus MC, Rotterdam, The Netherlands
    Mol Cell Endocrinol 286:199-205. 2008
    ..In this review an overview of the current insights into the role of SS and sst in the regulation of normal and pathological ACTH secretion is provided...
  5. ncbi The somatostatin receptor subtype 5 in neuroendocrine tumours
    Joost van der Hoek
    Department of Internal Medicine, Division of Endocrinology, Room Ee530b, Erasmus MC, Dr Molewaterplein 50, 3015 GE Rotterdam, The Netherlands
    Expert Opin Investig Drugs 19:385-99. 2010
    ....
  6. ncbi Responsiveness to somatostatin analog treatment and potentials of novel somatostatin analog
    L J Hofland
    Department of Internal Medicine, Section Endocrinology, Erasmus MC, Rotterdam, The Netherlands
    J Endocrinol Invest 26:8-13. 2003
  7. ncbi Pre-clinical and clinical experiences with novel somatostatin ligands: advantages, disadvantages and new prospects
    L J Hofland
    Department of Internal Medicine, Section Endocrinology, Erasmus MC, Rotterdam, The Netherlands
    J Endocrinol Invest 28:36-42. 2005
    ..However, every advantage has its disadvantage. Targeting multiple SSTR potentially induces more adverse effects as well. Especially, glucose homeostasis might induce new problems in the long-term use of universal ligands...
  8. ncbi The novel somatostatin analog SOM230 is a potent inhibitor of hormone release by growth hormone- and prolactin-secreting pituitary adenomas in vitro
    Leo J Hofland
    Department of Internal Medicine, Section of Endocrinology, Erasmus Medical Center, 3015 GD Rotterdam, The Netherlands
    J Clin Endocrinol Metab 89:1577-85. 2004
    ..Second, compared with OCT, SOM230 is more potent in inhibiting PRL release by mixed GH/PRL-secreting adenoma and prolactinoma cells...
  9. ncbi Role of somatostatin receptors in normal and tumoral pituitary corticotropic cells
    Leo J Hofland
    Department of Internal Medicine, Division of Endocrinology, Erasmus MC, Rotterdam, The Netherlands
    Neuroendocrinology 92:11-6. 2010
    ....
  10. ncbi Pituitary tumours: the sst/D2 receptors as molecular targets
    Leo J Hofland
    Department of Internal Medicine, Division of Endocrinology, Erasmus Medical Center, Rotterdam, The Netherlands
    Mol Cell Endocrinol 326:89-98. 2010
    ..In this review the current knowledge on the expression and functional roles of sst and D2 in pituitary tumours is discussed...
  11. ncbi Crucial role for somatostatin receptor subtype 2 in determining the uptake of [111In-DTPA-D-Phe1]octreotide in somatostatin receptor-positive organs
    Leo J Hofland
    Department of Internal Medicine Room Bd240, Erasmus Medical Center, Dr Molewaterplein 40, 3015 GD Rotterdam, The Netherlands
    J Nucl Med 44:1315-21. 2003
    ....
  12. ncbi Expression of somatostatin, cortistatin, and somatostatin receptors in human monocytes, macrophages, and dendritic cells
    Virgil A S H Dalm
    Dept of Internal Medicine, Rm Bd 240, Erasmus MC, Dr Molewaterplein 40, 3015 GD, Rotterdam, The Netherlands
    Am J Physiol Endocrinol Metab 285:E344-53. 2003
    ....
  13. ncbi Somatostatin receptors in pituitary function, diagnosis and therapy
    Leo J Hofland
    Section Endocrinology, Department of Internal Medicine, Erasmus MC, Rotterdam, The Netherlands
    Front Horm Res 32:235-52. 2004
    ..This review discusses the expression and potential role of sst subtypes in the different types of human pituitary adenomas...
  14. ncbi Induction of apoptosis with hybrids of Arg-Gly-Asp molecules and peptides and antimitotic effects of hybrids of cytostatic drugs and peptides
    Leo J Hofland
    Department of Internal Medicine, Erasmus Medical Center, Rotterdam, The Netherlands
    J Nucl Med 46:191S-8S. 2005
    ..Here we discuss the development of the different cytotoxic somatostatin analogs and their antitumor effects in vitro and in vivo in experimental models...
  15. ncbi The multi-ligand somatostatin analogue SOM230 inhibits ACTH secretion by cultured human corticotroph adenomas via somatostatin receptor type 5
    Leo J Hofland
    Department of Internal Medicine, Section of Endocrinology, Erasmus Medical Centre, GD Rotterdam, The Netherlands
    Eur J Endocrinol 152:645-54. 2005
    ..We compared the in vitro effects of the sst(2)-preferring SS analogue octreotide (OCT) and the multi-ligand SOM230 on ACTH release by human and mouse corticotroph tumour cells...
  16. ncbi Dissociation between the effects of somatostatin (SS) and octapeptide SS-analogs on hormone release in a small subgroup of pituitary- and islet cell tumors
    L J Hofland
    Department of Internal Medicine III, Erasmus University, Rotterdam, The Netherlands
    J Clin Endocrinol Metab 82:3011-8. 1997
    ..However, in the majority of NFAs and prolactinomas, DA-agonists were equally or more effective than SS in the suppression of tumoral secretion products...
  17. ncbi Interferon-alpha-2a is a potent inhibitor of hormone secretion by cultured human pituitary adenomas
    L J Hofland
    Department of Internal Medicine III, Erasmus University, Rotterdam, The Netherlands
    J Clin Endocrinol Metab 84:3336-43. 1999
    ....
  18. ncbi Differential regulation of human dopamine D2 and somatostatin receptor subtype expression by glucocorticoids in vitro
    C de Bruin
    Division of Endocrinology, Department of Internal Medicine, Erasmus Medical Center, s Gravendijkwal 230, 3015 CE Rotterdam, The Netherlands
    J Mol Endocrinol 42:47-56. 2009
    ..This mechanism may also be responsible for the low expression of sst(2) in corticotroph adenomas and underwrite the current interest in sst(5) and D(2) as possible therapeutic targets for a medical treatment of Cushing's disease...
  19. ncbi Evaluation of radiolabelled bombesin analogues for receptor-targeted scintigraphy and radiotherapy
    W A Breeman
    Department of Nuclear Medicine, University Hospital Dijkzigt, Rotterdam, The Netherlands
    Int J Cancer 81:658-65. 1999
    ..We conclude that [(111)In-DTPA-Pro1,Tyr4]BN has promising characteristics for applications in nuclear medicine...
  20. ncbi Pre-clinical comparison of [DTPA0] octreotide, [DTPA0,Tyr3] octreotide and [DOTA0,Tyr3] octreotide as carriers for somatostatin receptor-targeted scintigraphy and radionuclide therapy
    M De Jong
    Department of Nuclear Medicine, University Hospital Dijkzigt, Rotterdam, The Netherlands
    Int J Cancer 75:406-11. 1998
    ..Renal uptake of 111In-labelled [DTPA0]octreotide, [DTPA0,Tyr3]octreotide and [DOTA0,Tyr3]octreotide was reduced over 50% by an i.v. injection of 400 mg/kg D-lysine, whereas radioactivity in blood, pancreas and adrenals was not affected...
  21. ncbi Comparison of (111)In-labeled somatostatin analogues for tumor scintigraphy and radionuclide therapy
    M De Jong
    Department of Nuclear Medicine, University Hospital, Dijkigt, Rotterdam, The Netherlands
    Cancer Res 58:437-41. 1998
    ..In conclusion, radiolabeled [DTPA0,Tyr3]octreotide and, especially, [DTPA0,Tyr3]octreotate and their DOTA-coupled counterparts are most promising for scintigraphy and radionuclide therapy of SS receptor-positive tumors in humans...
  22. ncbi Blockade of the growth hormone (GH) receptor unmasks rapid GH-releasing peptide-6-mediated tissue-specific insulin resistance
    A F Muller
    Department of Internal Medicine, Erasmus Medical Center Rotterdam, 3015 Rotterdam, The Netherlands
    J Clin Endocrinol Metab 86:590-3. 2001
    ..As a mechanism of these GHRP-6-mediated metabolic changes in the nonfasting state, direct nonpituitary-mediated GHRP-6 effects on the gastroentero-hepatic axis seem probable...
  23. ncbi Mifepristone effects on tumor somatostatin receptor expression in two patients with Cushing's syndrome due to ectopic adrenocorticotropin secretion
    C de Bruin
    Department of Internal Medicine, Erasmus Medical Center, Gravendijkwal 230, 3015 CE Rotterdam, The Netherlands
    J Clin Endocrinol Metab 97:455-62. 2012
    ..Follow-up octreoscans after, respectively, 6 and 12 months showed the unequivocal presence of a bronchial carcinoid in both patients...
  24. ncbi Tissue distribution and metabolism of radioiodinated DTPA0, D-Tyr1 and Tyr3 derivatives of octreotide in rats
    W A Breeman
    Department of Nuclear Medicine, University Hospital Dijkzigt, Rotterdam, The Netherlands
    Anticancer Res 18:83-9. 1998
    ..CONCLUSION: The position of the Tyr residues and the addition of the DTPA group greatly influence the biodistribution of radioiodinated [Tyr]OCT analogs...
  25. ncbi Neuroendocrine aspects of immunolymphoproliferative diseases
    D Ferone
    Department of Internal Medicine, Erasmus University, Rotterdam, The Netherlands
    Ann Oncol 12:S125-30. 2001
    ..These concepts increase the possibility of a wider antitumor treatment with ligands for neuroepeptide receptors than in established 'classic' neuroendocrine tumors...
  26. ncbi Long-term treatment with the dopamine agonist quinagolide of patients with clinically non-functioning pituitary adenoma
    F R Nobels
    Department of Medicine, University Hospital Dijkzigt, Rotterdam, The Netherlands
    Eur J Endocrinol 143:615-21. 2000
    ....
  27. ncbi Fluconazole inhibits human adrenocortical steroidogenesis in vitro
    R van der Pas
    Division of Endocrinology, Department of Internal Medicine, Erasmus Medical Center, 3015 GE Rotterdam, The Netherlands
    J Endocrinol 215:403-12. 2012
    ..Furthermore, patients receiving fluconazole because of mycosis might be at risk for developing adrenocortical insufficiency...
  28. ncbi Future clinical prospects in somatostatin/cortistatin/somatostatin receptor field
    V A S H Dalm
    Department of Internal Medicine, Erasmus MC, Rotterdam, The Netherlands
    Mol Cell Endocrinol 286:262-77. 2008
    ..Moreover, the role of new SS analogues and new insights in sst physiology will be discussed...
  29. ncbi Neuropeptides and their receptors in the immune system
    P M van Hagen
    Department of Immunology, Erasmus University, Rotterdam, The Netherlands
    Ann Med 31:15-22. 1999
    ....
  30. ncbi Unacylated ghrelin acts as a potent insulin secretagogue in glucose-stimulated conditions
    Carlotta Gauna
    Division of Endocrinology, Department of Internal Medicine, Erasmus Medical Centre, Rotterdam, The Netherlands
    Am J Physiol Endocrinol Metab 293:E697-704. 2007
    ..Our data demonstrate that, in glucose-stimulated conditions, exogenous UAG acts as a potent insulin secretagogue, whereas endogenous AG exerts a maximal tonic inhibition on glucose-induced insulin release...
  31. ncbi Cushing's disease in dogs and humans
    C de Bruin
    Department of Internal Medicine, Division of Endocrinology, Erasmus Medical Center, Rotterdam, The Netherlands
    Horm Res 71:140-3. 2009
    ..The dog underwent curative transsphenoidal hypophysectomy and has remained in complete remission in the 3.5 years since surgery...
  32. ncbi In vivo and in vitro expression of somatostatin receptors in two human thymomas with similar clinical presentation and different histological features
    D Ferone
    Department of Internal Medicine, Erasmus Medical Center Rotterdam, The Netherlands
    J Endocrinol Invest 24:522-8. 2001
    ..Finally, although more cases need to be evaluated, the lack of detection of SS mRNA in the tumor presenting a more aggressive phenotype (B2 thymoma) might have physiopathological or prognostic significance...
  33. ncbi Effect of inflammatory cytokines and growth factors on tumour cell adhesion to the peritoneum
    M E van Rossen
    Laboratory for Experimental Surgery and Oncology, Erasmus University Rotterdam, Dr Molewaterplein 50, PO Box 1738, 3000 DR Rotterdam, The Netherlands
    J Pathol 193:530-7. 2001
    ..These results prove that IL-1beta and EGF are significant promoting factors in tumour cell adhesion to mesothelium in vitro and may therefore account for tumour recurrence in the peritoneum in vivo...
  34. ncbi Ghrelin and its unacylated isoform stimulate the growth of adrenocortical tumor cells via an anti-apoptotic pathway
    P J D Delhanty
    Department of Internal Medicine, Rm Ee542, Erasmus Medical Centre, Dr Molewaterplein 50, 3015 GE Rotterdam, The Netherlands
    Am J Physiol Endocrinol Metab 293:E302-9. 2007
    ....
  35. ncbi A small mammal model of tumour implantation, dissemination and growth factor expression after partial hepatectomy
    A G J Aalbers
    Department of Surgery, Erasmus Medical Centre, University Hospital Rotterdam, The Netherlands
    Eur J Surg Oncol 34:469-75. 2008
    ..Surgical resection remains the most effective therapy for metastatic colorectal cancer confined to the liver, although the extrahepatic recurrence rate is high...
  36. ncbi Somatostatin receptor subtype expression in human tumors
    L J Hofland
    Department of Internal Medicine, Erasmus University Medical Centre Rotterdam, The Netherlands
    Ann Oncol 12:S31-6. 2001
    ..Therefore, the characterisation of SSR subtypes in human tumors may have important clinical consequences...
  37. ncbi Somatostatin receptors in gastroentero-pancreatic neuroendocrine tumours
    W W de Herder
    Department of Internal Medicine, Erasmus MC, Dr Molewaterplein 40, 3015 GD Rotterdam, The Netherlands
    Endocr Relat Cancer 10:451-8. 2003
    ..Currently, [(111)In-DTPA(0)]octreotide, [(90)Y-DOTA(0),Tyr(3)]octreotide, [(177)Lu-DOTA(0)Tyr(3)]octreotate, [(111)In-DOTA(0)]lanreotide and [(90)Y-DOTA(0)]lanreotide can be used for this purpose...
  38. ncbi Expression and functional analysis of dopamine receptor subtype 2 and somatostatin receptor subtypes in canine cushing's disease
    C de Bruin
    Department of Internal Medicine, Division of Endocrinology, Erasmus Medical Center, Gravendijkwal 230, 3015 CE Rotterdam, The Netherlands
    Endocrinology 149:4357-66. 2008
    ....
  39. ncbi New somatostatin analogs: will they fulfil old promises?
    S W J Lamberts
    Department of Medicine, Erasmus Medical Centre, 40 Dr Molewaterplein, 3015 GD Rotterdam, The Netherlands
    Eur J Endocrinol 146:701-5. 2002
  40. ncbi Pre-clinical evaluation of [(111)In-DTPA-Pro(1), Tyr(4)]bombesin, a new radioligand for bombesin-receptor scintigraphy
    W A Breeman
    Department of Nuclear Medicine, University Hospital Dijkzigt, Rotterdam, The Netherlands
    Int J Cancer 83:657-63. 1999
    ..The CA20948 tumour, inoculated in the hindleg, was also visualized scintigraphically. [(111)In-DTPA-Pro(1), Tyr(4)]BN appears to be a promising radioligand for scintigraphy of BNR-expressing tumours...
  41. ncbi In vitro secretion of FSH by cultured clinically nonfunctioning and gonadotroph pituitary adenomas is directly correlated with locally produced levels of activin A
    H T Wessels
    Department of Endocrinology and Reproduction, Erasmus University Rotterdam, Rotterdam, The Netherlands
    Clin Endocrinol (Oxf) 54:485-92. 2001
    ..Since many of the NFAs and Gn-omas secrete FSH in vitro, we hypothesized that locally produced activin may stimulate secretion of FSH in these pituitary adenomas...
  42. ncbi Postoperative evaluation of patients with acromegaly: clinical significance and timing of oral glucose tolerance testing and measurement of (free) insulin-like growth factor I, acid-labile subunit, and growth hormone-binding protein levels
    R A Feelders
    Division of Endocrinology, Erasmus Medical Center, Rotterdam, The Netherlands
    J Clin Endocrinol Metab 90:6480-9. 2005
    ..It is not exactly known when patients with acromegaly should be evaluated for cure after transsphenoidal adenomectomy (TA)...
  43. ncbi There are no acute cardiac effects of a single iv dose of human ghrelin in severe growth hormone deficient patients
    J A M J L Janssen
    Department of Internal Medicine, Erasmus Medical Center, Rotterdam, The Netherlands
    J Endocrinol Invest 27:659-64. 2004
    ..This suggests that GH-independent effects of ghrelin play no important role in the acute regulation of cardiac function in man...
  44. ncbi Somatostatin and dopamine receptors as targets for medical treatment of Cushing's Syndrome
    C de Bruin
    Department of Internal Medicine, Erasmus Medical Center, Rotterdam, The Netherlands
    Rev Endocr Metab Disord 10:91-102. 2009
    ..Although selected cases of adrenal CS may benefit from sst or DA-targeted treatment, its total contribution to the treatment of these patients is likely to be low as surgery is effective in most cases...
  45. ncbi Immunohistochemical localization of somatostatin receptor sst2A in human rheumatoid synovium
    A M ten Bokum
    Department of Immunology, Erasmus University, Rotterdam, The Netherlands
    J Rheumatol 26:532-5. 1999
    ..To identify the somatostatin receptor-expressing cells in rheumatoid synovium using a recently developed antiserum directed against the somatostatin receptor subtype 2A (sst2A)...
  46. ncbi Quantitative and functional expression of somatostatin receptor subtypes in human thymocytes
    Diego Ferone
    Department of Internal Medicine, Erasmus Medical Center Rotterdam, 3015 GD Rotterdam, The Netherlands
    Am J Physiol Endocrinol Metab 283:E1056-66. 2002
    ....
  47. ncbi Correlation of in vitro and in vivo somatotropic adenoma responsiveness to somatostatin analogs and dopamine agonists with immunohistochemical evaluation of somatostatin and dopamine receptors and electron microscopy
    Diego Ferone
    Department of Internal Medicine, Erasmus Medical Center, 3015 GE Rotterdam, The Netherlands
    J Clin Endocrinol Metab 93:1412-7. 2008
    ..In nine cases, GH and PRL content was further studied by immunoelectron microscopy...
  48. ncbi Type I interferons in the treatment of pancreatic cancer: mechanisms of action and role of related receptors
    Giovanni Vitale
    Department of Internal Medicine, Erasmus MC, Rotterdam, The Netherlands
    Ann Surg 246:259-68. 2007
    ..We evaluated the role of type I interferons (IFNs) and IFN receptors in the regulation of cell growth in 3 human pancreatic adenocarcinoma cell lines (BxPC-3, MiaPaCa-2, and Panc-1)...
  49. ncbi The role of somatostatin analogs in Cushing's disease
    Joost van der Hoek
    Department of Internal Medicine, Section Endocrinology, Erasmus MC, 3015 Rotterdam, The Netherlands
    Pituitary 7:257-64. 2004
    ....
  50. ncbi Dopamine receptor expression and function in corticotroph pituitary tumors
    Rosario Pivonello
    Department of Internal Medicine, Erasmus Medical Center, 3015 GE Rotterdam, The Netherlands
    J Clin Endocrinol Metab 89:2452-62. 2004
    ..The effectiveness of cabergoline in normalizing cortisol secretion in 40% of cases supports its therapeutic use in the management of Cushing's disease...
  51. ncbi The pathophysiological consequences of somatostatin receptor internalization and resistance
    Leo J Hofland
    Department of Internal Medicine, Erasmus Medical Center, 3015 GD Rotterdam, The Netherlands
    Endocr Rev 24:28-47. 2003
    ..Herein, the development and potential role of novel somatostatin analogs is discussed...
  52. ncbi Addition of insulin glargine or NPH insulin to metformin monotherapy in poorly controlled type 2 diabetic patients decreases IGF-I bioactivity similarly
    A J Varewijck
    Department of Internal Medicine, Erasmus MC, Rotterdam, The Netherlands
    Diabetologia 55:1186-94. 2012
    ....
  53. ncbi Insulin glargine is more potent in activating the human IGF-I receptor than human insulin and insulin detemir
    A J Varewijck
    Department of Internal Medicine, Division of Endocrinology, Erasmus MC, Rotterdam, The Netherlands
    Growth Horm IGF Res 20:427-31. 2010
    ..To investigate whether human insulin (HI) and insulin analogues differ in their ability to activate the human IGF-I receptor (IGF-IR), the human insulin receptor A (IR-A) and the human insulin receptor B (IR-B) in vitro...
  54. ncbi Somatostatin modulates G-CSF-induced but not interleukin-3-induced proliferative responses in myeloid 32D cells via activation of somatostatin receptor subtype 2
    S P Oomen
    Institute of Hematology, Erasmus University Rotterdam, Rotterdam, The Netherlands
    Hematol J 2:322-9. 2001
    ..While 0.1-1 x 10(-9) M of somatostatin, or its synthetic stable analog octreotide, can inhibit G-CSF-induced proliferation of AML cells, little or no effects are seen on GM-CSF- or IL-3-induced responses...
  55. ncbi IGF-I bioactivity better reflects growth hormone deficiency than total IGF-I
    A J Varewijck
    Department of Internal Medicine, Division of Endocrinology, Erasmus Medical Center, 3015 CE Rotterdam, The Netherlands
    J Clin Endocrinol Metab 96:2248-54. 2011
    ..Recently a kinase receptor activation assay was developed to determine IGF-I bioactivity in human serum. The principle of this assay is based on quantification of IGF-I receptor activation after stimulation with serum in vitro...
  56. ncbi Tissue distribution of octreotide binding receptors in normal mice and strains prone to autoimmunity
    A M C Ten Bokum
    Department of Immunology, Erasmus Medical Centre Rotterdam, Dr Molewaterplein 40, 3015 GD Rotterdam, Netherlands
    Nucl Med Commun 23:1009-17. 2002
    ..To our knowledge, this is the first report on the tissue distribution of octreotide binding receptors in mice...
  57. ncbi Low circulating insulin-like growth factor I bioactivity in elderly men is associated with increased mortality
    M P Brugts
    Department of Internal Medicine, Erasmus Medical Center, Dr Molewaterplein 50, Rotterdam, The Netherlands
    J Clin Endocrinol Metab 93:2515-22. 2008
    ..The IGF-I kinase receptor activation assay is a novel method for measuring IGF-I bioactivity in human serum. We speculated that determination of circulating IGF-I bioactivity is more informative than levels of immunoreactive IGF-I...
  58. ncbi The role of somatostatin and somatostatin analogs in the pathophysiology of the human immune system
    V A S H Dalm
    Department of Internal Medicine, Erasmus MC, The Netherlands
    J Endocrinol Invest 26:94-102. 2003
  59. ncbi Weak estrogenic activity of phenol red in the culture medium: its role in the study of the regulation of prolactin release in vitro
    L J Hofland
    Department of Medicine, Erasmus University, Rotterdam, The Netherlands
    Mol Cell Endocrinol 54:43-50. 1987
    ....
  60. ncbi Functional role of somatostatin receptors in neuroendocrine and immune cells
    L J Hofland
    Department of Internal Medicine III, Erasmus University, Rotterdam, The Netherlands
    Ann Med 31:23-7. 1999
    ..The recent development of novel SS-R subtype-selective SS analogues will be helpful in unravelling the functional roles of the individual SS-R subtypes in SS-R-expressing human neuroendocrine and immune cells...
  61. ncbi Effects of type I interferons on IGF-mediated autocrine/paracrine growth of human neuroendocrine tumor cells
    Giovanni Vitale
    Department of Internal Medicine, Erasmus Medical Center, 3015 GE Rotterdam, The Netherlands
    Am J Physiol Endocrinol Metab 296:E559-66. 2009
    ....
  62. ncbi The hypercoagulable state in Cushing's disease is associated with increased levels of procoagulant factors and impaired fibrinolysis, but is not reversible after short-term biochemical remission induced by medical therapy
    R van der Pas
    Department of Internal Medicine, Division of Endocrinology, Erasmus Medical Centre, Room Ee 569, Dr Molewaterplein 50, 3015 GE Rotterdam, The Netherlands
    J Clin Endocrinol Metab 97:1303-10. 2012
    ..Cushing's disease (CD) is accompanied by an increased risk of venous thromboembolism. Surgery is the primary treatment of CD...
  63. ncbi Somatostatin receptor in human hepatocellular carcinomas: biological, patient and tumor characteristics
    C Verhoef
    Department of Surgery, Erasmus Medical Centre, Rotterdam, The Netherlands
    Dig Surg 25:21-6. 2008
    ..We investigated the sst2 expression in HCC and examined whether HCCs expressing sst2 are a distinct subgroup...
  64. ncbi Role of the mTOR pathway in normal and tumoral adrenal cells
    M C De Martino
    Department of Internal Medicine, Division of Endocrinology, Erasmus MC, Rotterdam, The Netherlands
    Neuroendocrinology 92:28-34. 2010
    ..Moreover, mTOR inhibitors, interfering with the activation of several mitogenic and angiogenic factors, could be considered as a novel treatment opportunity for the management of malignant adrenal tumors...
  65. ncbi Neuroendocrine tumor markers
    S W Lamberts
    Department of Medicine, University Hospital Dijkzigt, Erasmus University, 40 Dr Molewaterplein, 3015 GD Rotterdam, The Netherlands
    Front Neuroendocrinol 22:309-39. 2001
    ..Other markers, such as chromogranin A, neuron-specific enolase, and alpha-subunit, as well as peptide receptor visualization, are of increasing importance in the diagnosis and follow-up of neuroendocrine and non-neuroendocrine tumors...
  66. ncbi Effects of somatostatin analogs on a growth hormone-releasing hormone secreting bronchial carcinoid, in vivo and in vitro studies
    M van Hoek
    Department of Internal Medicine Bd289, Erasmus University Medical Center, P O Box 2040, 3000 CA Rotterdam, The Netherlands
    J Clin Endocrinol Metab 94:428-33. 2009
    ..The sst pattern in bronchial carcinoids and effects of SAs have not been extensively investigated, particularly not for the recently developed universal SA SOM230 (Pasireotide) that has high affinity for sst1, 2, 3, and 5...
  67. ncbi Coexpression of dopamine and somatostatin receptor subtypes in corticotroph adenomas
    Christiaan de Bruin
    Department of Internal Medicine, Division of Endocrinology, Erasmus Medical Center, Rotterdam, The Netherlands
    J Clin Endocrinol Metab 94:1118-24. 2009
    ..To what extent these receptor subtypes are coexpressed within individual adenomas, is not known however...
  68. ncbi Effects of acute administration of acylated and unacylated ghrelin on glucose and insulin concentrations in morbidly obese subjects without overt diabetes
    Rosalie M Kiewiet
    Division of Endocrinology and Metabolism, Department of Internal Medicine, University of Turin, Molinette Hospital, Corso Dogliotti 14, 10126, Turin, Italy
    Eur J Endocrinol 161:567-73. 2009
    ..To investigate the effects of unacylated ghrelin (UAG) and co-administration of acylated ghrelin (AG) and UAG in morbid obesity, a condition characterized by insulin resistance and low GH levels...
  69. ncbi Future treatment strategies of aggressive pituitary tumors
    Steven W J Lamberts
    Department of Internal Medicine, Division of Endocrinology, Erasmus Medical Center, 3015 CE Rotterdam, The Netherlands
    Pituitary 12:261-4. 2009
    ....
  70. ncbi The role of cortistatin in the human immune system
    P Martin van Hagen
    Department of Immunology, Erasmus Medical School, Rotterdam, The Netherlands
    Mol Cell Endocrinol 286:141-7. 2008
    ..On the basis of these promising results, studies aiming to further evaluate the possibilities of CST as a therapeutic agent in human immune-mediated inflammatory diseases are warranted...
  71. ncbi Intravenous glucose administration in fasting rats has differential effects on acylated and unacylated ghrelin in the portal and systemic circulation: a comparison between portal and peripheral concentrations in anesthetized rats
    Carlotta Gauna
    Division of Endocrinology, Department of Internal Medicine, Room Ee542, Erasmus Medical Center, Dr Molewaterplein 50, 3015 GE, Rotterdam, The Netherlands
    Endocrinology 148:5278-87. 2007
    ..Thus, our results suggest that peripheral AG metabolic regulation and action are mainly confined within the gastrointestinal tract...
  72. ncbi Somatostatin receptors in pheochromocytoma
    Wouter W de Herder
    Department of Internal Medicine, Section of Endocrinology, Erasmus MC, Rotterdam, The Netherlands
    Front Horm Res 31:145-54. 2004
  73. ncbi Normal values of circulating insulin-like growth factor-I bioactivity in the healthy population: comparison with five widely used IGF-I immunoassays
    Michael P Brugts
    Department of Internal Medicine, Erasmus MC, Dr Molewaterplein 50, Rotterdam, The Netherlands
    J Clin Endocrinol Metab 93:2539-45. 2008
    ..Recently an IGF-I-specific kinase receptor activation assay (KIRA) has been developed as an alternative method. However, no normative values have been established for the IGF-I KIRA...
  74. ncbi Somatostatin receptors in malignant lymphomas: targets for radiotherapy?
    Virgil A S H Dalm
    Department of Internal Medicine, Erasmus Medical Center, Rotterdam, The Netherlands
    J Nucl Med 45:8-16. 2004
    ..Therefore, we investigated in vitro the characteristics of lymphoma tissues and lymphoid cell lines to evaluate whether lymphomas can be targets for radiotherapy...
  75. ncbi Preclinical and clinical experiences with the role of somatostatin receptors in the treatment of pituitary adenomas
    Joost van der Hoek
    Department of Internal Medicine, Section Endocrinology, Room Ee30b, Erasmus MC, Dr Molewaterplein 50, 3015 GE, Rotterdam, The Netherlands
    Eur J Endocrinol 156:S45-51. 2007
    ..In the present review, the functional role of sst in all types of pituitary adenomas, based on recent preclinical and clinical studies, is being discussed...
  76. ncbi Ghrelin stimulates, whereas des-octanoyl ghrelin inhibits, glucose output by primary hepatocytes
    Carlotta Gauna
    Department of Internal Medicine, Section of Endocrinology, Erasmus MC, 3015 GE Rotterdam, The Netherlands
    J Clin Endocrinol Metab 90:1055-60. 2005
    ..These actions might be mediated by a different receptor than GHS-R1a, and apparently, we must consider AG and UAG as separate hormones that can modify each other's actions on glucose handling, at least in the liver...
  77. ncbi Distinct functional properties of native somatostatin receptor subtype 5 compared with subtype 2 in the regulation of ACTH release by corticotroph tumor cells
    Joost van der Hoek
    Dept of Internal Medicine, Section Endocrinology, Erasmus MC, 3015 GE Rotterdam, The Netherlands
    Am J Physiol Endocrinol Metab 289:E278-87. 2005
    ..In conclusion, our data support the concept that the sst5 receptor might be a target for new therapeutic agents to treat Cushing's disease...
  78. ncbi Novel subtype specific and universal somatostatin analogues: clinical potential and pitfalls
    Joost van der Hoek
    Department of Internal Medicine, Section Endocrinology, Erasmus MC, P O Box 1738, 3000 DR Rotterdam, The Netherlands
    Curr Pharm Des 11:1573-92. 2005
    ..Finally, acknowledged side effects and possible pitfalls of the use of SS-analogues are discussed...
  79. ncbi Distribution pattern of somatostatin and cortistatin mRNA in human central and peripheral tissues
    Virgil A S H Dalm
    Department of Internal Medicine, Josephine Nefkens Institute, Erasmus MC, Rotterdam, The Netherlands
    Clin Endocrinol (Oxf) 60:625-9. 2004
    ..CONCLUSION: CST may have a broader functional role than previously assumed...
  80. ncbi Unacylated ghrelin is active on the INS-1E rat insulinoma cell line independently of the growth hormone secretagogue receptor type 1a and the corticotropin releasing factor 2 receptor
    Carlotta Gauna
    Division of Endocrinology, Department of Internal Medicine, Erasmus MC, Dr Molewaterplein 50, 3015 GE, Rotterdam, The Netherlands
    Mol Cell Endocrinol 251:103-11. 2006
    ..Our data support the existence of a specific receptor for UAG, other than the CRF2R and GHS-R1a. The stimulatory effect on insulin secretion by AG in this cell line is mediated by the GHS-R1a...
  81. ncbi Medical treatment of Cushing's syndrome: adrenal-blocking drugs and ketaconazole
    Richard A Feelders
    Department of Internal Medicine, Endocrine Section, Erasmus Medical Center, Rotterdam, The Netherlands
    Neuroendocrinology 92:111-5. 2010
    ..e. the universal somatostatin analogue pasireotide and/or the dopamine agonist cabergoline, and low-dose ketoconazole seems a rational approach to achieve biochemical control...
  82. ncbi Somatostatin is a selective chemoattractant for primitive (CD34(+)) hematopoietic progenitor cells
    Sigrid P M A Oomen
    Institute of Hematology, Erasmus University Rotterdam, Rotterdam, The Netherlands
    Exp Hematol 30:116-25. 2002
    ..Despite the broad use of SST and its analogs in clinical practice, the spectrum of activities of SST is incompletely defined. Here, we examined the role of SST and its receptors in hematopoiesis...
  83. ncbi Dopamine receptor expression and function in corticotroph ectopic tumors
    Rosario Pivonello
    Department of Internal Medicine, Erasmus Medical Center, 3015 GE Rotterdam, The Netherlands
    J Clin Endocrinol Metab 92:65-9. 2007
    ..Dopamine receptor (DR) expression and dopamine agonist (DA) effectiveness have never been demonstrated in neuroendocrine tumors associated with ectopic ACTH syndrome (EAS)...
  84. ncbi The somatostatin analogue SOM230, compared with octreotide, induces differential effects in several metabolic pathways in acromegalic patients
    Joost van der Hoek
    Department of Internal Medicine, Section Endocrinology, Erasmus MC, Dr Molewaterplein 40, 3015 GD Rotterdam, The Netherlands
    Clin Endocrinol (Oxf) 63:176-84. 2005
    ..c. injection SOM230 100 and 250 microg, were compared to those following OCT 100 microg...
  85. ncbi Medical therapy of acromegaly: efficacy and safety of somatostatin analogues
    Richard A Feelders
    Department of Internal Medicine, Section of Endocrinology, Erasmus Medical Center, Rotterdam, The Netherlands
    Drugs 69:2207-26. 2009
    ....
  86. ncbi A single-dose comparison of the acute effects between the new somatostatin analog SOM230 and octreotide in acromegalic patients
    Joost van der Hoek
    Department of Internal Medicine, Section of Endocrinology, Erasmus Medical Center, 3015 GD Rotterdam, The Netherlands
    J Clin Endocrinol Metab 89:638-45. 2004
    ..We conclude that SOM230 is an effective GH-lowering drug in acromegalic patients with the potential to increase the number of patients controlled during long-term medical treatment...
  87. ncbi New developments in the medical treatment of Cushing's syndrome
    R van der Pas
    Division of Endocrinology, Department of Internal Medicine, Erasmus Medical Center, s Gravendijkwal 230, 3015 CE Rotterdam, The Netherlands
    Endocr Relat Cancer 19:R205-23. 2012
    ..In this review, results of preclinical and clinical studies with drugs that exert their action through these molecular targets, as well as already established medical treatment options, will be discussed...
  88. ncbi In vitro characterization of somatostatin receptors in the human thymus and effects of somatostatin and octreotide on cultured thymic epithelial cells
    D Ferone
    Department of Internal Medicine III, Erasmus University, Rotterdam, The Netherlands
    Endocrinology 140:373-80. 1999
    ..These data suggest a paracrine/autocrine role of SS and its receptors in the regulation of cell growth in thymic microenvironment...
  89. ncbi Discovery of iodinated somatostatin analogues selective for hsst2 and hsst5 with excellent inhibition of growth hormone and prolactin release from rat pituitary cells
    Sandra Blaj Moore
    University of California-San Diego, 9500 Gilman Drive, La Jolla, California 92093-0343, and Erasmus MC, Rotterdam, The Netherlands
    J Med Chem 48:6643-52. 2005
    ....
  90. ncbi IFN-beta is a highly potent inhibitor of gastroenteropancreatic neuroendocrine tumor cell growth in vitro
    Giovanni Vitale
    Department of Internal Medicine, Erasmus Medical Center, Rotterdam, The Netherlands
    Cancer Res 66:554-62. 2006
    ..Further studies are required to establish whether IFN-beta has comparable potent tumor growth inhibitory effects in vivo...
  91. ncbi Differential expression of somatostatin receptor subtypes in human peripheral blood mononuclear cell subsets
    Elgin G R Lichtenauer-Kaligis
    Department of Internal Medicine, Erasmus MC, Rotterdam, The Netherlands
    Eur J Endocrinol 150:565-77. 2004
    ....
  92. ncbi Administration of acylated ghrelin reduces insulin sensitivity, whereas the combination of acylated plus unacylated ghrelin strongly improves insulin sensitivity
    C Gauna
    Department of Medicine, Erasmus Medical Center, 3015 GE Rotterdam, The Netherlands
    J Clin Endocrinol Metab 89:5035-42. 2004
    ....
  93. ncbi Igf-I bioactivity in an elderly population: relation to insulin sensitivity, insulin levels, and the metabolic syndrome
    Michael P Brugts
    Department of Internal Medicine, Erasmus Medical Center, Rotterdam, The Netherlands
    Diabetes 59:505-8. 2010
    ..The purpose of our study was to investigate whether IGF-I bioactivity was related to insulin sensitivity and the metabolic syndrome...
  94. ncbi Influence of proinflammatory cytokines on the adhesion of human colon carcinoma cells to lung microvascular endothelium
    Miranda ten Kate
    Department of Surgery, Erasmus Medical Center, Rotterdam, The Netherlands
    Int J Cancer 112:943-50. 2004
    ..Probably not one but a complex of adhesion molecules is responsible for enhanced adhesion to HMVECs-L...
  95. ncbi Somatostatin and somatostatin receptors: from basic concepts to clinical applications
    Maria Cristina De Martino
    Department of Internal Medicine, Division of Endocrinology, Erasmus Medical Center, Rotterdam, The Netherlands
    Prog Brain Res 182:255-80. 2010
    ..The development of novel SS-analogues with new pharmacokinetic and pharmacodynamic characteristics may further improve the clinical applications of such compounds...
  96. ncbi In vivo and in vitro detection of dopamine d2 receptors in uveal melanomas
    Lisa Bodei
    Department of Nuclear Medicine, Erasmus University Medical Centre, Rotterdam, The Netherlands
    Cancer Biother Radiopharm 18:895-902. 2003
    ..Although further studies on larger series are needed, 123I-epidepride could represent a future tool to study the expression of D2R in other classes of neuroendocrine tumors...
  97. ncbi Somatostatin analogs in the diagnosis and treatment of cancer
    Steven W J Lamberts
    Dept Medicine, Erasmus Medical Centre, 40 Dr Molewaterplein, 3015 GD Rotterdam, The Netherlands
    Trends Endocrinol Metab 13:451-7. 2002
    ..Knowledge about the differential anti-tumor effects of the sst subtypes on tumor cells might have clinical significance after the development of new subtype-specific somatostatin analogs...
  98. ncbi The role of superoxide anions in the development of distant tumour recurrence
    M ten Kate
    Department of Surgery, Erasmus MC, Dr Molewaterplein 40, 3015 GD Rotterdam, The Netherlands
    Br J Cancer 95:1497-503. 2006
    ..This indicates that by tackling the production of ROS preventing tumour recurrence at distant sites might be feasible...
  99. ncbi Associations between promoter usage and alternative splicing of the glucocorticoid receptor gene
    Henk Russcher
    Department of Internal Medicine, Erasmus MC, University Medical Center Dr Molewaterplein 40, Rotterdam, The Netherlands
    J Mol Endocrinol 38:91-8. 2007
    ..This indicates that regulation of GR splice variants could partly occur through selective use of the multiple promoters, and that this is another way to sensitize cells and tissues to the different activities of the GR isoforms...
  100. ncbi Novel insights in dopamine receptor physiology
    Rosario Pivonello
    Departments of Internal Medicine, Erasmus Medical Center, Rotterdam, The Netherlands, Molecular and Clinical Endocrinology and Oncology, Federico II University, Via Sergio Pansini, 5, 80131 Naples, Italy
    Eur J Endocrinol 156:S13-21. 2007
    ..In addition, the recent findings on the relationship between dopamine receptors and neuroendocrine tumors are summarized...
  101. ncbi Pro-inflammatory cytokines affect pancreatic carcinoma cell. Endothelial cell interactions
    Miranda ten Kate
    Department of Surgery, Erasmus Medical Center, Rotterdam, The Netherlands
    JOP 7:454-64. 2006
    ..The potential role of surgery-induced pro-inflammatory cytokines on the development of tumor recurrence in pancreatic cancer was investigated...